MP Debate: Expanding Access to Medical Cannabis on NHS

A cross-party group of Members of Parliament has tabled a motion in the House of Commons calling for a formal review of NHS prescribing criteria for cannabis-based medicinal products (CBMPs). The Early Day Motion, which has attracted signatures from members across multiple parties, argues that current eligibility thresholds are leaving tens of thousands of patients without affordable access to clinically appropriate treatment.

Core Arguments Raised

Supporters of the motion highlighted the stark disparity between the number of patients receiving CBMPs through private clinics — estimated at over 130,000 — and those receiving treatment through the NHS, which the motion puts at under 1,000. MPs argued that this gap creates a two-tier healthcare system in which access to medical cannabis is determined by personal wealth rather than clinical need.

Government Response

The Minister for Health, responding in the chamber, acknowledged the concerns raised but noted that the government's position remains aligned with NICE guidance. Officials stated that NHS prescribing decisions must be driven by a robust evidence base and that the reclassification debate is ongoing within relevant clinical advisory bodies.

Patient Advocacy

• The UK Medical Cannabis Registry has submitted written evidence to the Health and Social Care Committee
• Patient groups representing chronic pain, PTSD, and epilepsy communities gave oral testimony
• Over 12,000 individuals signed a related public petition within the first week of its launch

"No one should be forced to choose between managing their condition and paying their rent. Medical cannabis must become a real option on the NHS."

A formal parliamentary inquiry has not yet been confirmed, but the motion has prompted committee interest and is expected to generate an official government response within 60 days.